<DOC>
	<DOC>NCT00597818</DOC>
	<brief_summary>The primary purpose of this study is to determine the efficacy and safety of three dose levels of cobiprostone as compared to placebo in OA/RA patients treated with an NSAID.</brief_summary>
	<brief_title>Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Patient is more than 40 and less than 70 years of age. Patient has confirmed osteoarthritis (OA) and/or rheumatoid arthritis (RA) and could benefit from NSAID therapy. No current gastrointestinal H. pylori infection. Known allergy or hypersensitivity to NSAIDs, or has any other contraindicated condition(s) to NSAID therapy. Patient has undergone a gastrointestinal or abdominal surgical procedure within 90 days prior to the Screening Visit, or has had a bowel resection at any time. Medical history includes prior or active GI complications and/or disorders, including but not limited to Barrett's esophagus, erosive esophagitis, esophageal stricture or ring, gastric obstruction, irritable bowel syndrome (IBS), or inflammatory bowel disease (IBD). Active symptomatic peptic ulcer disease or GI bleeding. Patient has received cobiprostone (SPI8811; RU8811) or AMITIZA (lubiprostone, SPI0211, or RU0211) at any time prior to participation in this study.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>